Literature DB >> 3194939

Effect of cyclosporine on plasma lipids and modification with dietary fish oil.

A M Jevnikar1, R Petric, B J Holub, D J Philbrick, W F Clark.   

Abstract

Hyperlipidemia is an identified risk factor for atherosclerosis in patients following renal transplantation that may be related to previous uremia and various drugs including steroids. Recent evidence has suggested that treatment with cyclosporine may be an independent risk factor for development of hyperlipidemia in some patients. Twenty-four Sprague Dawley rats were given CsA at 30 mg/kg by gavage for 28 days in 1 ml of olive oil or fish oil vehicle, and compared with controls receiving just vehicle. Increases of both triglyceride (233.6%) and cholesterol (50.9%) were observed in olive oil/CsA animals (P less than .01), with no significant change noted with either vehicle alone. An increase of triglyceride from baseline was observed with fish oil/CsA (119%) (P less than .01) but was significantly less than the increase with olive oil/CsA animals (P less than .05). No increase in cholesterol was found in CsA-treated rats using the fish oil vehicle. The mechanisms leading to hyperlipidemia with four weeks of CsA administration in these rats are unknown, but may be related to altered hepatic synthesis. CsA levels were lower in fish oil-treated animals, possibly explaining the difference noted in lipid levels--or, alternatively, reduction of plasma lipoproteins may have altered drug kinetics and CsA binding. This work emphasizes a need for further study of lipids in CsA-treated patients, and advises some caution in the use of lipoprotein-reducing agents in patients using CsA without consideration of the possible effect on free drug levels.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3194939     DOI: 10.1097/00007890-198811000-00018

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  12 in total

Review 1.  The cyclosporins.

Authors:  Z Rehácek
Journal:  Folia Microbiol (Praha)       Date:  1995       Impact factor: 2.099

Review 2.  Post-transplant hyperlipidaemia.

Authors:  R M Jindal
Journal:  Postgrad Med J       Date:  1997-12       Impact factor: 2.401

Review 3.  Chimerism-based tolerance in organ transplantation: preclinical and clinical studies.

Authors:  T Oura; A B Cosimi; T Kawai
Journal:  Clin Exp Immunol       Date:  2017-04-20       Impact factor: 4.330

Review 4.  The pathophysiology of Sandimmune (cyclosporine) in man and animals.

Authors:  J Mason
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

Review 5.  The pathophysiology of Sandimmune (cyclosporine) in man and animals.

Authors:  J Mason
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

6.  Vascular effects of cyclosporine A in vivo and in vitro.

Authors:  G Ferns; M Reidy; R Ross
Journal:  Am J Pathol       Date:  1990-08       Impact factor: 4.307

Review 7.  Long-term dietary habits and interventions in solid-organ transplantation.

Authors:  Stuart M Zeltzer; David O Taylor; W H Wilson Tang
Journal:  J Heart Lung Transplant       Date:  2015-07-06       Impact factor: 10.247

8.  Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate.

Authors:  M deLorgeril; P Boissonnat; C A Bizollon; J Guidollet; G Faucon; J P Guichard; R Levy-Prades-Sauron; S Renaud; G Dureau
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

9.  Dose response of fish oil versus safflower oil on graft arteriosclerosis in rabbit heterotopic cardiac allografts.

Authors:  K L Yun; J I Fann; M H Sokoloff; L G Fong; G E Sarris; M E Billingham; D C Miller
Journal:  Ann Surg       Date:  1991-08       Impact factor: 12.969

Review 10.  Endocrine and metabolic abnormalities following kidney transplantation.

Authors:  W H Hörl; W Riegel; C Wanner; M Haag-Weber; P Schollmeyer; H Wieland; H Wilms
Journal:  Klin Wochenschr       Date:  1989-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.